中剂量阿糖胞苷治疗老年急性髓系白血病患者的临床评价

Clinical evaluation of middle dose cytarabine in the treatment of elderly patients with acute myeloid leukemia

目的:通过实际调查分析老年急性髓系白血病初治患者诱导缓解之后应用中剂量阿糖胞苷巩固治疗的疗效和患者治疗之后的不良反应发生状况。方法:收治急性髓系白血病初治患者94例,分为两组,分析两组患者的一般资料、总生存时间、生存率、复发率和不良反应发生情况。结果:对两组患者3年无复发生存率、累计复发率、中位无复发生存率比较,中剂量阿糖胞苷治疗可以提高老年急性髓系白血病患者的临床治疗效果。两组患者不良反应差异无统计学意义。结论:应用中剂量阿糖胞苷治疗,可以大大提高患者的临床疗效,降低患者的累计复发率,提高老年患者3年无复发生存率。

Objective:Through the actual investigation and analysis of the efficacy of the application of medium-dose cytarabine consolidation therapy and the occurrence of adverse reactions after treatment in patients with newly diagnosed acute myeloid leukemia.Methods:94 cases of newly diagnosed patients with acute myeloid leukemia,divided into two groups,analysis of general data, overall survival,survival,recurrence and adverse events in both groups.Result:Comparison of 3-year recurrence-free survival rate, cumulative recurrence rate and median recurrence-free survival rate in the two groups,middle-dose cytarabine treatment can improve the clinical treatment effect of elderly patients with acute myeloid leukemia.There was no significant difference in adverse reactions between the two groups.Conclusion:Application of medium dose cytarabine treatment,can greatly improve the clinical efficacy of patients,reduce the cumulative recurrence rate of patients,and improve 3-year recurrence-free survival in elderly patients.